APVO Aptevo Therapeutics Inc

Price (delayed)

$3.4

Market cap

$4.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$78.78

Enterprise value

-$5.87M

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel bispecific and trispecific immunotherapies for the treatment of cancer. Aptevo's pipeline includes two clinical candidates and multiple preclinical programs spanning ...

Highlights
The company's debt fell by 4.5% QoQ
APVO's EPS has dropped by 102% year-on-year but it is up by 10% since the previous quarter
Aptevo Therapeutics's equity has decreased by 33% QoQ
The quick ratio has contracted by 15% from the previous quarter

Key stats

What are the main financial stats of APVO

APVO stock price

How has the Aptevo Therapeutics stock price performed over time
Intraday
-2.86%
1 week
-16.46%
1 month
-18.07%
1 year
-90.11%
YTD
-63.94%
QTD
-23.42%

Financial performance

How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.67M
Net income
-$26.26M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 11% YoY
APVO's net income is down by 11% YoY

Price vs fundamentals

How does APVO's price correlate with its fundamentals

Growth

What is Aptevo Therapeutics's growth rate over time

Valuation

What is Aptevo Therapeutics stock price valuation
P/E
N/A
P/B
0.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APVO's EPS has dropped by 102% year-on-year but it is up by 10% since the previous quarter
APVO's P/B is 88% below its 5-year quarterly average of 2.8 and 13% below its last 4 quarters average of 0.4
Aptevo Therapeutics's equity has decreased by 33% QoQ

Efficiency

How efficient is Aptevo Therapeutics business performance
The return on equity has surged by 73% year-on-year and by 24% since the previous quarter
The company's return on invested capital fell by 40% YoY and by 2.1% QoQ
Aptevo Therapeutics's ROA has increased by 29% YoY and by 12% from the previous quarter

Dividends

What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APVO.

Financial health

How did Aptevo Therapeutics financials performed over time
APVO's total assets is 140% higher than its total liabilities
APVO's total assets has soared by 139% YoY but it is down by 27% QoQ
The total liabilities has contracted by 16% YoY and by 16% from the previous quarter
The company's debt is 62% lower than its equity
The debt to equity has soared by 113% YoY and by 41% QoQ
Aptevo Therapeutics's equity has decreased by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.